ViiV tops reputation survey while Gilead suffers on pricing issues
This article was originally published in Scrip
Executive Summary
For the second year in a row, ViiV Healthcare has topped the reputation ranks for pharma companies in a survey of patient organizations. But Gilead, for whom 2014 should have been a year patients celebrated, slipped 12 places as a result of pricing controversies.